Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Julie Kanter, MD, Darla Liles, MD, Rodolfo Cancado, MD, PhD, João Friedrisch, MD PhD, Troy H. Guthrie, MD, Jennifer Knight-Madden, MBBS, PhD, Ofelia A. Alvarez, MD, Victor R. Gordeuk, MD, Sandra Gualandro, MD PhD, Marina Pereira Collela, MD PhD, Wally R. Smith, MD, Scott A. Rollins, PhD, Jonathan W. Stocker, PhD, Russell P. Rother, PhD

Blood (2016) 128 (22): 1.

https://doi.org/10.1182/blood.V128.22.1.1

Published: 2016

Journal Articles

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Jonathan W. Stocker, PhD, Debra Mandarino, MD, Ziad Kawar, PhD, Richard Alvarez, MBA, David Falconer, MS, MBA, Scott A. Rollins, PhD, Russell P. Rother, PhD

Blood (2013) 122 (21): 970.

https://doi.org/10.1182/blood.V122.21.970.970

Published: 2013

Journal Articles

Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease

Alexander Röth, Andreas Hüttmann, Russell P. Rother, Ulrich Dührsen, Thomas Philipp

Blood (2009) 113 (16): 3885–3886.

https://doi.org/10.1182/blood-2009-01-196329

Published: 2009

Journal Articles

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Richard Kelly, MD, Louise Arnold, BSc, MA, Stephen J. Richards, PhD, Anita Hill, MD, Charlotte Bomken, MD, John Hanley, MD, Andrew Loughney, MD, PhD, Gus Khursigara, PhD, Russell P. Rother, PhD, Elizabeth Chalmers, MD, Edward Fitzsimons, MD, Ryotaro Nakamura, MD, Anna Gaya, MD, Bruno Rotoli, MD, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Peter Hillmen, MB, PhD

Blood (2008) 112 (11): 4576.

https://doi.org/10.1182/blood.V112.11.4576.4576

Published: 2008

Journal Articles

Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Richard Kelly, MD, Louise Arnold, BSc, MA, Stephen Richards, PhD, Anita Hill, MD, Sandra vanBijnen, MD, Petra Muus, MD, PhD, Donna Dorr, RN, MSN, AOCN, Robert Brodsky, MD, Gus Khursigara, PhD, Russell P. Rother, PhD, Peter Hillmen, MBChB, PhD

Blood (2008) 112 (11): 3441.

https://doi.org/10.1182/blood.V112.11.3441.3441

Published: 2008

Journal Articles

Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab.

Jens Nuernberger, Oliver Witzke, Russell P. Rother, PhD, Thomas Philipp, Udo Vester, Hideo Baba, Lothar Bernd Zimmerhackl, Andreas Kribben

Blood (2008) 112 (11): 2294.

https://doi.org/10.1182/blood.V112.11.2294.2294

Published: 2008

Journal Articles

Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria

Anita Hill, MD, Russell P. Rother, PhD, Xunde Wang, MD, Robert J Sapsford, MD, Paul O Collinson, MD, David C Gaze, PhD, Sidney M Morris, Jr., PhD, Andrew Scally, Kerry Quinn-Senger, PhD, Stephen J Richards, PhD, Monica Bessler, MD, PhD, Richard Kelly, MD, Peter Hillmen, MBChB, PhD, Mark Gladwin, MD

Blood (2008) 112 (11): 486.

https://doi.org/10.1182/blood.V112.11.486.486

Published: 2008

Journal Articles

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky, Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gaya, Luke Coyle, Carlos de Castro, Chieh-Lin Fu, Jaroslaw P. Maciejewski, Monica Bessler, Henk-André Kroon, Russell P. Rother, Peter Hillmen

Blood (2008) 111 (4): 1840–1847.

https://doi.org/10.1182/blood-2007-06-094136

Published: 2008

Journal Articles

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria

Peter Hillmen, Petra Muus, Ulrich Dührsen, Antonio M. Risitano, Jörg Schubert, Lucio Luzzatto, Hubert Schrezenmeier, Jeffrey Szer, Robert A. Brodsky, Anita Hill, Gerard Socié, Monica Bessler, Scott A. Rollins, Leonard Bell, Russell P. Rother, Neal S. Young

Blood (2007) 110 (12): 4123–4128.

https://doi.org/10.1182/blood-2007-06-095646

Published: 2007

Includes: Supplemental data

Journal Articles

Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria.

Gerard Socié, MD, PhD, Peter Hillmen, MB ChB, Petra Muus, MD, PhD, Jörg Schubert, MD, Ulrich Dührsen, DM, Antonio M. Risitano, MD PhD, Russell P. Rother, PhD, Robert A. Brodsky, MD, Jeffrey Szer, MB BS

Blood (2007) 110 (11): 3672.

https://doi.org/10.1182/blood.V110.11.3672.3672

Published: 2007

Journal Articles

High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Peter Hillmen, MB, ChB, Modupe O. Elebute, MD, Richard Kelly, MD, Alvaro Urbano-Ispizua, MD, Russell P. Rother, PhD, Chieh-Lin Fu, MD, Paul Browne, MB

Blood (2007) 110 (11): 3678.

https://doi.org/10.1182/blood.V110.11.3678.3678

Published: 2007

Journal Articles

Prevention of Graft-Versus-Host Disease in Mouse Model Using Anti-Mouse C5 Antibody.

Jun-ichi Nishimura, MD, PhD, Divino DeOliveira, Benny J. Chen, MD, Yuzuru Kanakura, MD, PhD, Russell P. Rother, PhD, Nelson J. Chao, MD, MBA

Blood (2007) 110 (11): 3245.

https://doi.org/10.1182/blood.V110.11.3245.3245

Published: 2007

Journal Articles

The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Peter Hillmen, MB, PhD, Petra Muus, MD, PhD, Ulrich Dührsen, DM, Antonio M. Risitano, MD, PhD, Jörg Schubert, MD, Neal S. Young, MD, Hubert Schrezenmeier, MD, Jeffrey Szer, MB, BS, Robert A. Brodsky, MD, Anita Hill, MB, MD, Gérard Socié, MD, PhD, Scott A. Rollins, PhD, Russell P. Rother, PhD, Leonard Bell, MD, Lucio Luzzatto, MD

Blood (2006) 108 (11): 123.

https://doi.org/10.1182/blood.V108.11.123.123

Published: 2006

Journal Articles

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Jörg Schubert, MD, Peter Hillmen, MB, PhD, Ulrich Dührsen, DM, Neal S. Young, MD, Modupe Elebute, MB, MD, Jeffrey Szer, MB, BS, Giacomo Gianfaldoni, MD, Gérard Socié, MD, PhD, Paul Browne, MD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Petra Muus, MD, PhD

Blood (2006) 108 (11): 124.

https://doi.org/10.1182/blood.V108.11.124.124

Published: 2006

Journal Articles

High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis.

Anita Hill, MD, Scott A. Reid, PhD, Russell P. Rother, PhD, Mark T. Gladwin, MD, Paul O. Collinson, PhD, David C. Gaze, PhD, Angela Lowe, DCR, Ashley Guthrie, FRCR, Mohan U. Sivananthan, MD, Peter Hillmen, PhD

Blood (2006) 108 (11): 979.

https://doi.org/10.1182/blood.V108.11.979.979

Published: 2006

Journal Articles

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Neal S. Young, MD, Elisabetta Antonioli, MD, Bruno Rotoli, MD, Hubert Schrezenmeier, MD, Jörg Schubert, MD, Alvaro Urbano-Ispizua, MD, Luke Coyle, MD, Carlos de Castro, MD, Chieh-Lin Fu, MD, Jaroslaw P. Maciejewski, MD, PhD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Peter Hillmen, MB PhD

Blood (2006) 108 (11): 971.

https://doi.org/10.1182/blood.V108.11.971.971

Published: 2006

Journal Articles

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

Anita Hill, MD, Russell P. Rother, PhD, Antonio M. Risitano, PhD, Duncan S. Cole, PhD, Matthew J. Cullen, MSc, Stephen J. Richards, PhD, Carmine Selleri, MD, Patrizia Ricci, BSc, Bruno Rotoli, MD, Lucio Luzzatto, PhD, Peter Hillmen, PhD

Blood (2006) 108 (11): 972.

https://doi.org/10.1182/blood.V108.11.972.972

Published: 2006

Journal Articles

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Anita J. Dickinson, MSc, Anita Hill, MD, David Buchanon, MA, Louise Arnold, BSc, Modupe Elebute, MD, Russell P. Rother, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 1047.

https://doi.org/10.1182/blood.V106.11.1047.1047

Published: 2005

Journal Articles

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

Anita Hill, Peter Hillmen, Stephen J. Richards, Dupe Elebute, Judith C. Marsh, Jason Chan, Christopher F. Mojcik, Russell P. Rother

Blood (2005) 106 (7): 2559–2565.

https://doi.org/10.1182/blood-2005-02-0564

Published: 2005

Journal Articles

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibody

Paul J. Tacken, I. Jolanda M. de Vries, Karlijn Gijzen, Ben Joosten, Dayang Wu, Russell P. Rother, Susan J. Faas, Cornelis J. A. Punt, Ruurd Torensma, Gosse J. Adema, Carl G. Figdor

Blood (2005) 106 (4): 1278–1285.

https://doi.org/10.1182/blood-2005-01-0318

Published: 2005

Includes: Multimedia, Supplemental data

NARROW

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab.

Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria

Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria.

High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Prevention of Graft-Versus-Host Disease in Mouse Model Using Anti-Mouse C5 Antibody.

The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis.

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibody

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only